Merrimack Pharma (MACK) Misses Q1 EPS by 12c, Miss on Revenues

Merrimack Pharma (NASDAQ: MACK) reported Q1 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $24.12 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• UBS Upgrades InterContinental Hotels Group (IHG:LN) (IHG) to Buy
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue